High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapySignificant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients.Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy.Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Radiotherapy and Hormone Treatment in Prostate CancerDo androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study.The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma.Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.[No evidence for improved outcome with salvage radiotherapy for asymptomatic biochemical prostate cancer recurrence after prostatectomy by additive androgen suppression].Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre.Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancerImpact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.A retrospective study of late adverse events in proton beam therapy for prostate cancer.Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients.Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy.Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.[Radiation therapy of locally advanced prostate cancer].Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study.Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
P2860
Q26744606-C482467B-0966-4FB1-88B7-79BCAF34B06CQ28829239-7AE2D10E-46B6-49C5-A8EA-FE18B80FF23BQ30489515-E7141E43-6058-4CD5-B697-C84164DE3B23Q33466062-B009F8AF-378C-4CC7-8C17-F09A3AA6DC63Q36385462-FA914B6F-D0A9-4FE8-8985-A05635521C9FQ36474222-36D543C5-BEC6-4893-A435-D0193AD92064Q37176612-F28AB73B-AE25-4D32-BCF6-C9983F357D89Q37321037-F04CE57D-568E-4D5E-ABCE-D35C19E19D9FQ37624321-AE3D344B-FA10-4B88-94E5-82D187DA3613Q38673916-85150217-85DA-4533-B4B4-CDAF967E6D71Q38809393-6A1E35D1-1C58-4176-8DEF-237AD4A04BC8Q38890711-BD099DE3-CAB5-4EFD-BA57-64541BBCF6E3Q38910225-DD1E8F68-65C6-43F5-B73F-CBE34FD24FA5Q39006967-E275598A-8CD0-4AB0-BF10-CF7E63665B65Q39373854-0018575D-3878-459B-AD24-841B88E4F169Q39712837-E7676308-3B8E-430A-A556-457AB25FAF29Q39756984-BA4B8427-72C8-456B-BF8A-7EE27C36B314Q40026302-5E960E29-A382-41F8-A3D1-E2B04EA80872Q40400351-D6306549-53D6-43DE-BA9D-CF25AFAD070CQ40447684-6821D7C7-1C4A-4177-AF8F-5C25A878EFAAQ40959972-EE44B909-5CDC-40C4-8315-3317A53526EAQ41039697-22E64EFB-347F-4578-9E86-27BB8AF75DDCQ41486881-C89FD0CE-EB8B-4978-AD3D-B4A9C4FD5196Q42376337-9E5F2014-0E84-4BA1-AE6F-587D75630E11Q42687909-48A6D8D5-3617-4007-B05B-F120484DD1C0Q47100168-8826CA73-68BA-4C89-A534-DF64C2B5498AQ48234904-74B9CFDA-D18C-4646-A558-F5D170D83136Q48276400-84CD05FC-8969-4CB9-9D37-0D956BA5D061Q48348802-108E2038-2ADF-499C-AA03-39602C05D9AAQ49567687-EEC21013-C060-43E7-B46A-8D525F038838Q49803982-F945066E-FC35-4348-B0A0-FF6E6D53704EQ50260314-EE10B00E-38BF-423F-8A2D-5251C75EFC6CQ52593552-A50CA2FF-2B15-4639-A031-01C4E91B8379Q53766555-1FBD1A8D-BA44-4D0F-89CE-7AA16857F90AQ57112442-FB0D685E-50DC-4CC5-A942-FF6B318F251F
P2860
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
High-dose radiotherapy with sh ...... ed, controlled, phase 3 trial.
@en
type
label
High-dose radiotherapy with sh ...... ed, controlled, phase 3 trial.
@en
prefLabel
High-dose radiotherapy with sh ...... ed, controlled, phase 3 trial.
@en
P2093
P1433
P1476
High-dose radiotherapy with sh ...... ed, controlled, phase 3 trial.
@en
P2093
Agustí Pedro Olive
Aitor Perez de la Haza
Almudena Zapatero
Ana Alvarez
Ana Boladeras
Araceli Guerrero
Carmen Gonzalez San Segundo
Carmen Martín de Vidales
Felipe A Calvo
Francesc Casas
P304
P356
10.1016/S1470-2045(15)70045-8
P577
2015-02-19T00:00:00Z